Healthcare / Drug Manufacturers - Specialty & GenericNSE
$590.00
-16.20 (-2.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $737.7M · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11.8B
P/E
13.4x
↓EV/EBITDA
8.9x
↓ROE
11.6%
↑Gross Margin
53.6%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+9.9%
FCF CAGR
+47.6%
FCF margin
12.0%
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.71B · net income $878.9M · FCF $803.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.71B | $6.71B | $6.23B | $5.81B | $5.05B |
| Net Income | $878.9M | $878.9M | $823.5M | $933.0M | $729.0M |
| EBITDA | $1.31B | $1.31B | $1.24B | $1.34B | $1.11B |
| EPS | 43.88 | 43.88 | 41.11 | 46.58 | 36.40 |
| Gross Margin | 53.6% | 53.6% | 53.3% | 52.1% | 51.9% |
| Operating Margin | 12.4% | 12.4% | 14.2% | 15.4% | 16.0% |
| Net Margin | 13.1% | 13.1% | 13.2% | 16.1% | 14.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | — | 0.00 | 0.00 |
| Cash Flow | |||||
| Free Cash Flow | $803.2M | $803.2M | $737.7M | $236.0M | $249.8M |
| Returns | |||||
| ROE | 11.6% | 11.6% | 12.3% | 15.7% | 14.5% |
| Valuation | |||||
| P/E | 13.44 | 13.44 | 13.75 | 13.23 | 10.10 |
| EV/EBITDA | 8.88 | 8.88 | 9.02 | 9.19 | 6.59 |
| P/B | 1.56 | 1.56 | 1.69 | 2.08 | 1.47 |
| Growth & Yield | |||||
| Revenue Growth | 7.7% | 7.7% | 7.4% | 15.0% | — |
| EPS Growth | 6.7% | 6.7% | -11.7% | 28.0% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
6.1%
EPS terminal req.
$52.35
Spread vs growth
0.7%
5Y implied EPS CAGR
7.6%
EPS terminal req.
$63.35
Spread vs growth
-0.9%
10Y implied EPS CAGR
8.8%
EPS terminal req.
$102.02
Spread vs growth
-2.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.7%
Start / end P/E
13.4x → 13.4x
EPS bridge
41.11 → 43.88
Residual
+0.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.